This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery (ERICCA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University College, London
ClinicalTrials.gov Identifier:
NCT01247545
First received: November 22, 2010
Last updated: May 28, 2015
Last verified: May 2015
November 22, 2010
May 28, 2015
November 2010
March 2015   (Final data collection date for primary outcome measure)
Major adverse cardiac and cerebral events [ Time Frame: One year post-surgery ]
Combined endpoint of Cardiovascular death, MI, Revascularisation and Stroke.
Major adverse cardiac and cerebral events [ Time Frame: One year post-surgery ]
Combined endpoint of Cardiovascular death, Reinfarction, Revascularisation and Stroke.
Complete list of historical versions of study NCT01247545 on ClinicalTrials.gov Archive Site
  • Peri-operative myocardial injury [ Time Frame: 72 hours peri-operative period ]
    72 hours area under curve serum troponin-T
  • LV ejection fraction [ Time Frame: At one year ]
    Echo determined LV ejection fraction
  • Acute kidney injury [ Time Frame: Peri-operative ]
    Acute kidney injury score and 24 hour area under curve serum NGAL
  • 30 day MACCE [ Time Frame: 30 days post surgery ]
    Major adverse cardiac and cerebral events 30 days post surgery
  • All cause death [ Time Frame: 1 year post surgery ]
  • Length of ITU stay [ Time Frame: ITU stay ]
  • Length of hospital stay [ Time Frame: Until hospital discharge ]
  • Inotrope score [ Time Frame: 72 hours post surgery ]
    Inotrope score after 72 hours
  • 6 minute Walk Test [ Time Frame: 6 weeks and 12 months post surgery ]
  • Quality of Life [ Time Frame: 6 weeks, 3/6/9 and 12 months post surgery ]
    Quality of Life assessed using the EQ-5D measurement
  • Peri-operative myocardial injury [ Time Frame: 72 hours peri-operative period ]
    72 hours area under curve serum troponin-T
  • LV ejection fraction [ Time Frame: At one year ]
    Echo determined LV ejection fraction
  • Acute kidney injury [ Time Frame: Peri-operative ]
    Acute kidney injury score and 24 hour area under curve serum NGAL
Not Provided
Not Provided
 
Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery
Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in Coronary Artery Bypass Graft Surgery

Coronary heart disease (CHD) is the leading cause of death in the UK, accounting for 124,000 deaths (2006) and costing the UK economy over £7.9 billion a year. Patients with severe CHD are usually treated by coronary artery bypass graft (CABG) surgery, the risks of which are increasing due to older and sicker patients being operated on. New treatment strategies are therefore required to improve health outcomes in these high-risk patients undergoing CABG with or without valve (CABG±valve) surgery.

The hypothesis tested in this research proposal is that remote ischaemic preconditioning (RIC), a virtually cost-free, non-pharmacological and simple non-invasive strategy for reducing the damage to the heart muscle at the time of surgery, improves health outcomes in high-risk patients undergoing CABG±valve surgery.

In this research project, 1610 high-risk patients undergoing CABG±valve surgery will be recruited via 28 UK hospitals performing heart surgery. Patients will be randomly allocated to receive either RIC or control. For RIC, a blood pressure cuff will be placed on the upper arm to temporarily deprive it of oxygen and nutrients, an intervention which has been shown in the investigators pilot studies to reduce damage to the heart muscle by up to 40% during CABG±valve surgery. The investigators will determine whether RIC can improve health outcomes in terms of better patient survival, less heart attacks and strokes, shorter hospital stay; less damage to the heart, kidney and brain during surgery; better heart function post-surgery and less chance of developing heart failure; better exercise tolerance and quality of life.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Coronary Heart Disease
  • Procedure: Remote ischaemic preconditioning
    Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
  • Procedure: Control
    Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
  • Placebo Comparator: Control
    Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
    Intervention: Procedure: Control
  • Active Comparator: Remote ischaemic conditioning
    Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
    Intervention: Procedure: Remote ischaemic preconditioning

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1612
March 2015
March 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients undergoing CABG with or without valve surgery using blood cardioplegia
  2. Patients aged 18 years and above
  3. Patients with an additive Euroscore greater than or equal to 5

Exclusion Criteria:

  1. Cardiogenic shock
  2. Cardiac arrest on current admission
  3. Pregnancy
  4. Significant peripheral arterial disease affecting the upper limbs
  5. Patients with significant hepatic dysfunction (Prothrombin>2.0 ratio)
  6. Patients with significant pulmonary disease (FEV1<40% predicted)
  7. Patients with known renal failure with a GFR<30 mL/min/1.73 m2
  8. Patients on glibenclamide or nicorandil, as these medications may interfere with RIC
  9. Patients recruited into another study which may impact on the ERICCA study
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT01247545
10/0303
Yes
Not Provided
Not Provided
University College, London
University College, London
Not Provided
Principal Investigator: Derek J Hausenloy, MD PhD University College, London
University College, London
May 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP